NCT Number: NCT02713022
Body Composition and White Adipose Tissue Inflammation
The investigators want to find a better way to predict the risk of having fatty tissue inflammation by using a different approach to finding out body fat composition. In this study, the investigators want to estimate the body fat composition using a DEXA scan. DEXA stands for dual energy X-ray absorptiometry. It is the standard and established test to determine bone mineral density (how strong the bones are) to diagnose osteoporosis. This test can also be used to determine the body composition including percent body fat and lean mass. The investigators will compare the participants DEXA scan results for body fat composition to the inflammation found in the breast tissue from the mastectomy to see if there is a relationship. If successful, this may help us predict which patients may be at risk for breast cancer in the future. In addition, the investigators will compare the participants DEXA scan results for body fat composition and inflammation found in the fat tissue from the mastectomy or prostatectomy to the level of exercise activity as measured by a short questionnaire to see if there is a relationship. The investigators will also measure the participants waist to hip ratio.
Finally, at the time the participant has blood drawn for their standard presurgical testing, the investigators will also test the blood for prediabetes using a blood test called hemoglocin A1c. The investigators will also measure for the participants waist to hip ratio, and a Hgb A1c blood drawn will be take at the time of presurgical testing. If not feasible, Hgb A1c can be drawn at a separate visit prior to the DEXA scan. If successful, this may help us predict which patients may be at risk for breast cancer in the future.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Waters Corporation (Data Analysis Only), Milford, Massachusetts, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age ≥ 18
- Female
- All BMIs
- Patients undergoing mastectomy at MSKCC (i.e. Nipple-sparing mastectomy, skin-sparing mastectomy, simple mastectomy, modified radical mastectomy, radical mastectomy); mastectomy may be either prophylactic or therapeutic. OR
- Patients undergoing hysterectomy at MSKCC
- History of prior breast surgeries/procedures is acceptable
Exclusion criteria
- Pregnancy (confirmed or suspected);
- Inability to lay supine on equipment table and maintain the position for the necessary time;
- Weight superior to the maximum allowed by the DEXA machine (over 350 lbs or 158 kg);
- Greater than 10% baseline weight loss in the past year;
- Planned surgical procedure is not a Mastectomy (i.e. breast conservation surgery or other non-mastectomy procedure; such as lumpectomy) or hysterectomy
- Metastatic cancer
- History of Wasting Syndromes or Cachexia
- Use of daily NSAIDs, aspirin, or steroids (other than inhaled or topical) within 30 days of surgery
- Use of neoadjuvant systemic or radiation therapy.
Treatment and study plan
Godin Leisure Time Exercise Questionnaire (GLTEQ)
BehavioralPrimary outcomes
-
fat percentage
Time frame: 1 year
as measured by DEXA
-
presence of White Adipose Tissue Inflammation (WATi )
Time frame: 1 year
as measured by DEXA
Sponsors and collaborators
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Collaborators
- Weill Medical College of Cornell University
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2023
- Study completion
- 2023
- First posted
- Mar 18, 2016
- Registry last updated
- Nov 8, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
African Cancer Genome: GMD
NCT05754658
Breast Cancer, Breast Diseases
Philadelphia, Pennsylvania, United States
View Trial Details'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
NCT04553926
Adnexal Diseases, Breast Cancer
Ansan, South Korea
View Trial DetailsA Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
NCT02009449
Adenocarcinoma, Adnexal Diseases
Los Angeles, California, United States
View Trial DetailsAdapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
NCT04000880
Adnexal Diseases, Behavior
Birmingham, Alabama, United States
View Trial Details